In Vivo Tracking of Cell Therapies for Cardiac Diseases with Nuclear Medicine

Abstract EN

Even though heart diseases are amongst the main causes of mortality and morbidity in the world, existing treatments are limited in restoring cardiac lesions.

Cell transplantations, originally developed for the treatment of hematologic ailments, are presently being explored in preclinical and clinical trials for cardiac diseases.

Nonetheless, little is known about the possible efficacy and mechanisms for these therapies and they are the center of continuous investigation.

In this scenario, noninvasive imaging techniques lead to greater comprehension of cell therapies.

Radiopharmaceutical cell labeling, firstly developed to track leukocytes, has been used successfully to evaluate the migration of cell therapies for myocardial diseases.

A substantial rise in the amount of reports employing this methodology has taken place in the previous years.

We will review the diverse radiopharmaceuticals, imaging modalities, and results of experimental and clinical studies published until now.

Also, we report on current limitations and potential advances of radiopharmaceutical labeling for cell therapies in cardiac diseases.